3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thrombosis
2
Pancreatic Neoplasms
2
Thromboembolism
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Ovarian Neoplasms
1
Obesity
1
Multiple Myeloma
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Embolism and Thrombosis
1
Embolism
1
Duodenal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
88
Fluorouracil
71
Paclitaxel
69
Radiotherapy
63
Oxaliplatin
55
Irinotecan
37
Docetaxel
36
Carboplatin
36
Leucovorin
34
Capecitabine
28
Radiation
25
Surgical Procedures, Operative
22
Drug Therapy
19
pembrolizumab
18
Cetuximab
15
Bevacizumab
15
Nivolumab
14
tislelizumab
12
camrelizumab
11
Neoadjuvant Therapy
11
Esophagectomy
11
Chemoradiotherapy
11
S 1 (combination)
10
Albumin-Bound Paclitaxel
10
nimotuzumab
9
Trastuzumab
9
durvalumab
8
Radiotherapy, Intensity-Modulated
8
Gefitinib
7
Epirubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Esophageal Neoplasms
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled